Table 1.

Clinical characteristics of the PD patients

Patient	Age	Gender	Disease duration (years)	UPDRS off	UPDRS on	l-DOPA dose per day	Contacts R/L	Motor states studied
P1	45	M	3	33	21	a	0–1	Both
							0–2
P2	65	M	18	33	8	1725	2	Off
							1
P3	62	F	20	52	23	1570	2	Off
							2
P4	58	M	17	62	24	1430	1–2	Both
							0–3
P5	58	M	19	27	3	900	1–3	Both
							2
P6	55	M	10	42	19	1600	1	Both
							1–3
P7	60	M	11	30	10	1925	2	Both
							3
P8	59	M	11	34	15	875	1–2	Both
							1–2
P9	54	M	10	55	23	1605	2–3	Both
							1–3
P10	67	F	10	45	15	1275	2–1	Both
							2–1
P11	67	M	13	27	13	500	3	Both
							3
P12	67	M	10	33	10	1000	1	On
							1
P13	47	M	12	44	17	875b	2–0	Both
							1–3
P14	59	M	11	34	21	525b	1–3	Both
							1
P15	55	F	7	27	14	1615	2–3	Both
							3

The UPDRS scores are the motor subscale scores (UPDRS-III) before surgery. The l-DOPA dose includes the equivalent dose of all dopaminergic drugs taken by each patient in milligrams per day (100 mg of standard levodopa = 130 mg of controlled-released levodopa = 10 mg of bromocriptine = 1 mg of pergolide = 1 mg of lisuride = 1 mg of pramipexole = 5 mg of ropinirole). The contacts used for final programming in each patient are indicated in the last column.

^aSustained dopaminergic treatment was suppressed at the time of surgery because of gastrointestinal intolerance.

^bThe patient was also given continuous apomorphine infusion of a total dose of ∼100 mg/d.